Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide in Polymorphic Light Eruption
NCT04704713Phase 3Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- May 2010
- Primary completion
- Dec 2010
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 3 trial of Afamelanotide in polymorphic light eruption (PMLE), sponsored by Clinuvel Pharmaceuticals. Started May 2010; status: completed.
02
Drugs
Afamelanotide
03
Conditions
polymorphic light eruption (PMLE)
Beyond the preview
Go deeper on NCT04704713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704713.